HC Wainwright & Co. Reiterates Buy on Reviva Pharmaceuticals, Maintains $14 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Reviva Pharmaceuticals (NASDAQ:RVPH) with a Buy and maintains $14 price target.

BenzingaJun 20 06:15 ET

H.C. Wainwright Maintains Reviva Pharmaceuticals(RVPH.US) With Buy Rating, Cuts Target Price to $14

H.C. Wainwright analyst Ram Selvaraju maintains $Reviva Pharmaceuticals(RVPH.US)$ with a buy rating, and adjusts the target price from $20 to $14.According to TipRanks data, the analyst has a success

moomoo NewsJun 11 06:31 ET · Ratings

Reviva Pharm Holdings Is Maintained at Buy by HC Wainwright & Co.

Reviva Pharm Holdings Is Maintained at Buy by HC Wainwright & Co.

Dow JonesJun 11 06:26 ET

Express News | HC Wainwright & Co. Maintains Buy on Reviva Pharmaceuticals, Lowers Price Target to $14

BenzingaJun 11 06:16 ET

Express News | Reviva Announces Closing of $3 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules

ReutersMay 29 16:45 ET

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CUPERTINO, Calif., May 29, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva" or the "Company"), a late-stage pharmaceutical company developing therapies that seek to address unm

Reviva PharmaceuticalsMay 29 00:00 ET